Wang (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
https://doi.org/10.1016/ S0140-6736(20)31022-9
https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31022-9.pdf
Treatment
Treatment for COVID-19 (Treated with remdesivir vs. Not received)
COVID-19 (clinical improvement)
Hazard ratio: 1.230 (0.870-1.750) Univariate analysis

China

Randomized clinical trial

Primary data collection

237

adults (aged ?18 years) admitted to hospital with severe COVID-19 (158 to remdesivir and 79 to placebo)

RT-PCR positive for SARS-CoV-2 patients, had pneumonia, confirmed by chest imaging, had oxygen saturation of 94% or lower on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and were within 12 days of symptom onset. The median age of study patients was 65 years (IQR 56–71); sex distribution was 89 (56%) men versus 69 (44%) women in the remdesivir group and 51 (65%) versus 27 (35%) in the placebo group

Total

37 Day


COVID-19 (clinical improvement)

0

Time to clinical improvement


Treatment

Treatment for COVID-19

remdesivir treatment

Not received

Treated with remdesivir


Hazard ratio

1.230 (0.870-1.750)

No

No

No

none


none

Average

No